🔗 Share this article

An underground economy for unlicensed weight-loss drugs is propelled by TikTok fitness influencers and vendors on communication apps, according to recent findings.

Experimental Drug Gaining Traction Online

The experimental drug, which remains in research studies, is being advertised by social media influencers for its supposed fat-burning properties. Viewers are urged to message these accounts directly for source information, while also obtaining promotional offers.

Active Trade on Social Networks

Separately, a flourishing trade exists on messaging services, where groups with thousands of members share “before and after” photos, injection guides and claims of rapid UK delivery. Sellers promote the drug there before directing buyers to WhatsApp for transactions.

Understanding Retatrutide

This medication is an investigational injectable created by American pharmaceutical company Eli Lilly. The treatment affects three intestinal hormones – GLP-1, glucose-dependent insulinotropic polypeptide and glucagon. Early trials suggest it could help patients reduce up to a quarter of their total weight. Nicknamed the “triple G”, the substance is being promoted online as the next Ozempic.

Healthcare Experts Express Worries

However, doctors and chemists have cautions that the distribution of what is still an unlicensed drug in the UK is a cause for concern and could lead to users administering products of unknown origin.

Several experts said the popularity for the experimental drug could be connected to the increasing cost of licensed weight loss products such as Mounjaro.

Legal Status and Implementation

Marketing retatrutide on social media or Telegram is prohibited in the UK, as it is an unlicensed drug that cannot be promoted or distributed for human use under the British medical regulations.

Some content creators attempt to circumvent the rules by referring to the drug as a “research chemical” or citing it as “not for human consumption”. The substance is not a controlled substance, but promotion and supply can still violate pharmaceutical, marketing, and customer regulations, risking penalties, legal action or imprisonment.

Platform Reaction and Material Elimination

Based on the social media company, the platform has removed violative content and prohibited associated hashtags and query recommendations. The organization stated it was committed to maintaining the service secure and allocating resources in enhancing compliance measures.

Online Trading Operations

Investigations also discovered communities with up to nine thousand participants selling retatrutide using Telegram's built-in discovery tool, which operates like a public directory. Entering “retatrutide” immediately displays groups with thousands of users, populated with photos of slimming results, glowing testimonials and detailed instructions for mixing or injecting at home.

Within minutes of entering one community, a seller posted contact information, where the majority of purchases occur. The vendor sent an guidebook and promised delivery within two days. When questioned whether the substance was genuine, one seller responded: “You can’t be sure.” Another provided a photo of a alleged testing documentation. Not one asked about weight, medical conditions or previous experience.

Item Details and Pricing

Within these communities, messages display dark colored packages with postal service labels, stating to contain fresh supplies. One communication stated: “It took eight of us to load them this morning.”

Buyers can choose between dry substance containers, prepared at residence with purified liquid, or pre-filled injectors typically priced at £160 for 20mg. When asked how much time a pen should last, sellers give contradictory answers ranging from a few weeks to “depends on your body”.

Platform Oversight and Safety Measures

A spokesperson for Telegram stated it actively moderated dangerous content on its service including content that promoted the “misuse of controlled medications”. The organization noted that it removed “millions of pieces of harmful content each day”.

Medical Expert Warnings

“People are injecting substances they cannot confirm. Even if the research behind retatrutide is sound, these digital versions may not include what they claim,” stated Jason Murphy, the director of pharmacy at a pharmacy service.

A medical professional of Asda Online Doctor connected the increase in interest to recent cost increases for approved weight-loss medications such as Mounjaro. “With costs increasing, individuals are turning to online platforms. But counterfeit treatments are highly risky. You cannot know what’s inside or whether the environment they were made in was clean,” she said.

Her team has previously seen patients harmed by self-injection from unconfirmed suppliers. “We understand the frustration, but purchasing from messaging apps or communication platforms is gambling with your well-being,” stated the doctor. “These materials could be contaminated or improperly measured.”

Producer Statement

A representative from the pharmaceutical company stated retatrutide was in phase 3 clinical trials and had not been evaluated or authorized by any regulatory agency globally. “Consequently at this point no one can market [it] for human use,” they said, adding that any item “falsely representing itself as a Lilly experimental product not yet approved … may expose patients to potentially serious medical dangers”.